Pogalizumab is an investigational humanized monoclonal antibody that targets and acts as an agonist of the co-stimulatory receptor OX40 (CD134). It is designed for cancer immunotherapy, with the goal of enhancing anti-tumor immune responses by directly activating OX40-positive T cells, thereby promoting their proliferation, survival, and effector function.